Over eighty million people in the U.S. are affected by inflammation and acute pain. Inflammation is a natural biological response to injury or infectious attack to the human body. Unregulated inflammation results in a broad range of conditions, most of which are classified by the tissue or organ where the inflammation occurs. These conditions include rheumatoid arthritis (RA) in the joint, psoriasis in the skin, chronic obstructive pulmonary disease (COPD) in the lung, fibrotic disease in the liver and kidney, Crohn’s disease in the intestine, congestive heart failure and atherosclerosis in the arteries, among others. We are developing drugs that modulate important biological targets in key intracellular pathways that control inflammation, potentially providing the ability to treat multiple diseases and conditions with a single oral agent. Currently, some of the most effective treatments for these diseases are injectable protein therapeutics, which have significant cost and patient compliance issues. Injectable protein therapeutics currently on the market, such as Enbrel®, Remicade®, Humira® and Kineret®, bind to and / or modulate the activity of the inflammatory cytokines TNF or IL-1 and are utilized for the treatment of RA, psoriasis and Crohn’s disease. We believe there are significant opportunities to creating orally active drugs that treat many of these often-chronic diseases.

Current Activities:

• Top-line Phase 2 results for p38 inhibitor, ARRY-797, in an inflammatory pain trial showed that it achieved its primary and secondary endpoints for analgesic efficacy and was well tolerated.
• We are initiating a Phase 2 trial with our MEK inhibitor ARRY-162, in Rheumatoid Arthritis patients.